Navigation Links
Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
Date:11/1/2007

eport on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Merck Forward-looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.


'/>"/>
SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... kidneys for transplantation. One solution is to increase the ... recent paper in the November issue of the journal ... strategies that have been developed to increase the number ... the adoption of these strategies at a single center. ...
... Italian epidemiologist as done a systematic review of various studies ... The study is focused to find out the link between ... believed that use of MMR vaccine shots in children’s may ... children around the world and concluded that MMR shots are ...
... characterized by progressive memory loss, decline in language skills ... to ageing population.// ,A recent paper in ... strategies in drug discovery. Hong-Yu Zhang, the author of ... one-drug-one-target strategy in drug discovery is limited, which has ...
... Acute ischemic stroke attributable to extracranial internal carotid artery ... death. // ,In selected cases, re-vascularization with carotid ... rate, and clinical outcomes in consecutive case series are ... a balloon-tipped catheter is inserted into an artery and ...
... Singh and Union Health Minister Anbumani Ramadoss are to convene ... problem of bird flu epidemic. //Awareness of bird flu and ... to the Western countries. The World Health Organization has sent ... if there are any possible flu attack. Dr. Anbumani said ...
... Professor Hans Theodor Eich and his colleagues from University ... radiation in Hodgkin’s Lymphoma patients undergoing chemotherapy does not ... reducing the side effects of radiation therapy. The results ... Therapeutic Radiology and Oncology. The researchers have reduced the ...
Cached Medicine News:Health News:Strategies To Boost Living Donor Kidney Transplants 2Health News:MMR Vaccination not linked to Autism 2
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional ... Toronto -based 3D visualization leader ... Congress of Neurological Surgeons Annual Meeting that they ... for brain surgery. The collaboration is the first ... combination to improve patient outcomes. NICO,s BrainPath® interventional ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho ... Co., Ltd. ( Japan ), announced ... granted Fast Track designation for TAS-102 (nonproprietary names: ... drug under investigation for the treatment of refractory ... has initiated a rolling NDA submission to the ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, ... treated with infliximab, a biologic therapy that has been used to ... diseases, including rheumatoid arthritis, Crohn,s disease and ulcerative colitis. , ... Human anti-chimeric antibody (HACA) ...
... May 13 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today it will be ... 2010 , at 8:45 a.m. Eastern Time .   , ... webcast of the presentation can be accessed via Zimmer,s Investor Relations website at http://investor.zimmer.com . ... , , About ...
Cached Medicine Technology:Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy 2Zimmer Holdings to Present at Baird's 2010 Growth Stock Conference 2
... addition to the Primus family of fine ... of speed and accuracy in a flexible ... testing. Test results in 2 minutes using ... lab or clinic., ,The PDQ system comes ...
Metrika's A1cNow Monitor is the first ever single-use test for hemoglobin A1c, it is the "gold standard" indicator of diabetes management. The test is easy to use, needs only a drop of blood and take...
... The intelligent CELL-DYN WorkCell delivers complete hematology ... operator safety. A modular configuration provides the ... basic system includes one Navigator module, one ... main bar code reader. The basic system ...
... The STart 4 semi-automated hemostasis ... of electro-mechanical clot detection (Viscosity-based Detection ... lipemic, icteric or other optically turbid ... analyzer offers programmable and preprogrammed assays ...
Medicine Products: